DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
Manufacturer cash-pay prices for the four brand-name GLP-1s, tracked since Jun 2024 and expressed as an index (base 100). The list price barely moved — the real story is in the manufacturer-direct programs.
| Drug | Jun 2024 mfg cash | Now | Change |
|---|---|---|---|
| Wegovy | $1,349 | $499 | -63% |
| Ozempic | $997 | $499 | -50% |
| Zepbound | $1,059 | $549 | -48% |
| Mounjaro | $1,025 | $549 | -46% |
Sticker (cash-retail) prices barely moved over the period. The drop is almost entirely in manufacturer-direct cash-pay programs — NovoCare (Wegovy) and LillyDirect (Zepbound, Mounjaro) — launched and repeatedly cut to compete with compounded telehealth. For an uninsured patient, the manufacturer-direct vial route is now roughly half what it cost in Jun 2024.
LoseLab GLP-1 Price Index (base 100 = Jun 2024). As of May 2026, the index stood at 47.3 — manufacturer cash prices down 53% over the period. loselab.com/price-index
Methodology. The index is the simple average of manufacturer cash-pay (mfg-direct) prices for Wegovy, Zepbound, Ozempic, and Mounjaro at each common quarterly snapshot, normalized to 100 at Jun 2024. Snapshots are LoseLab editorial captures from manufacturer programs (NovoCare, LillyDirect) and published cash prices, refreshed monthly; values carry forward between captures. This is cash-pay only — insured copays and compounded routes are tracked separately on each drug’s cost guide.